Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Aimovig is a prescription medicine containing erenumab-aooe, a monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor. It is approved for preventive treatment of migraine in adults. Aimovig is given as a subcutaneous injection once each month. It comes in single-dose prefilled autoinjectors and syringes containing either 70 mg or 140 mg.
read more about aimovig ...Erenumab-aooe binds to the calcitonin gene-related peptide receptor and blocks receptor function. CGRP signaling is involved in migraine biology. Blocking the receptor reduces CGRP activity and decreases migraine frequency in treated adults. Aimovig targets the receptor rather than the CGRP molecule itself and is intended for migraine prevention rather than treatment of an individual migraine attack.
Aimovig is approved for preventive treatment of migraine in adults. It is used in people with episodic or chronic migraine when a clinician selects CGRP-receptor therapy as part of preventive care. Aimovig is not labeled as an acute treatment taken to stop a migraine attack after symptoms begin. Safety and efficacy in pediatric patients have not been established.
Aimovig is injected under the skin once monthly. The recommended dose is 70 mg, while selected patients receive 140 mg once monthly. Injection sites include the abdomen, thigh, or upper arm. Patients and caregivers can administer the medicine after proper training. The prefilled device should sit at room temperature for at least 30 minutes before injection and should not be shaken.
Serious risks include hypersensitivity reactions, severe constipation complications, new or worsening high blood pressure, and new or worsening Raynaud's phenomenon. Injection-site reactions and constipation are among the more common adverse reactions reported in trials. Severe constipation, facial swelling, trouble breathing, marked blood pressure changes, or painful color changes in fingers or toes need medical evaluation.
Yes. Aimovig is approved for preventive treatment of migraine in adults. It is not labeled as an acute migraine treatment.
Aimovig is injected under the skin once each month. The labeled doses are 70 mg and 140 mg.
Yes. Patients or caregivers can administer Aimovig after proper training in preparation, injection technique, and device use.
Constipation is a reported adverse reaction. Serious constipation complications requiring hospitalization or surgery have also been reported after treatment.
AIMOVIG (erenumab-aooe) Full Prescribing Information. https://www.pi.amgen.com/united_states/aimovig/Aimovig_pi_hcp_english.pdf. Date Accessed September 11, 2026.
AIMOVIG 140 mg/mL Instructions for Use. https://www.pi.amgen.com/united_states/aimovig/Aimovig_ifu_140_english.pdf. Date Accessed September 11, 2026.
AIMOVIG 70 mg/mL Instructions for Use. https://www.pi.amgen.com/united_states/aimovig/Aimovig_ifu_hcp_pt_english.pdf. Date Accessed September 11, 2026.
DailyMed - AIMOVIG (erenumab-aooe) Injection. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b998ed05-94b0-47fd-b28f-cddd1e128fd8. Date Accessed September 11, 2026.
Erenumab-aooe Injection. https://medlineplus.gov/druginfo/meds/a618029.html. Date Accessed September 11, 2026.